Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269982 · ClinicalTrials.gov registry record
Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 120
- Enrollment target
NCT02269982 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 120 participants.
The verdict
NCT02269982 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This study will develop a first-in-man CTC-based molecular taxonomy of CRPC in the context of novel AR-directed therapies, categorize different patterns of resistance in this disease setting, and describe their evolution over time and treatment.
Interventions
- DEVICE AR-v7 assays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2019-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269982
The ClinicalTrials.gov registry entry for NCT02269982 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR-v7 assays is the first listed.
NCT02269982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02269982 about?
NCT02269982 is a clinical study titled "Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY". This study will develop a first-in-man CTC-based molecular taxonomy of CRPC in the context of novel AR-directed therapies, categorize different patterns of resistance in this disease setting, and describe their evolution over time and treatment.
What is the current status of trial NCT02269982?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2015-05-14. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT02269982?
The interventions under investigation include: AR-v7 assays (DEVICE).
Who is sponsoring clinical trial NCT02269982?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.